Devyser Diagnostics AB announces today that it has received Medical Device Single Audit Program (MDSAP) certification for its quality management system (QMS) for both Devyser assays and…
Devyser´s annual report 2023 has today been published on the company´s website. The report is available on: https://investors.devyser.com/en/reports-presentations The financial year…
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is valid for a period of up to four years. Indicative order value is estimated to be…
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA (dd-cfDNA) in the setting of multiple kidney transplantations” was published in the…
“Devyser is able to report strong sales growth and record high gross margins for the fourth quarter. During the quarter, Devyser continued to demonstrate the competitiveness of its…
On Tuesday February 20 at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q4 2023 report (which will have been published earlier on February 20 at 07.30 CET).…
Devyser is today announcing the strengthening and expanding of its management team as of February 1, 2024. Michael Uhlin, who has been Devyser’s CSO since the fall of 2023, will join the…
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first commercial agreement with UK based diagnostics company Cyted. The initial period for the…
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for screening and confirmation of cystic fibrosis. The tender with the University Hospital…
Devyser Diagnostics AB has entered an in vitro diagnostic development agreement with Illumina, Inc. (Nasdaq: ILMN). The agreement enables Devyser to develop and offer its in vitro…
